Protara Says Phase 2 Bladder Cancer Trial Shows 72% Complete Response Rate at 6 Months

MT Newswires Live

Dec 05, 2024

Protara Therapeutics (TARA) said Thursday that its investigational therapy TARA-002 demonstrated a complete response rate of 72% at six months in a phase 2 trial involving patients with non-muscle invasive bladder cancer.

The company said the complete response rate across Bacillus Calmette-Guerin exposures reached 70% at any time, with 100% of patients maintaining complete response and two of three patients sustaining response at nine months.

Protara said it expects international site expansion to accelerate enrollment and plans to share initial data from 12 months in mid-2025.

The investigational drug showed a favorable safety and tolerability profile, with no grade 2 or greater treatment-related adverse events, the company added.

Shares of the company surged more than 128% in recent premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2489430468"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2489430468\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2489430468?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-05 22:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2489430468","market":"us","top_or_hot":-1,"title":"Protara Says Phase 2 Bladder Cancer Trial Shows 72% Complete Response Rate at 6 Months","media":"MT Newswires Live","content":"<html><body><p> Protara <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TARA) said Thursday that its investigational therapy TARA-002 demonstrated a complete response rate of 72% at six months in a phase 2 trial involving patients with non-muscle invasive bladder cancer.</p><p>The company said the complete response rate across Bacillus Calmette-Guerin exposures reached 70% at any time, with 100% of patients maintaining complete response and two of three patients sustaining response at nine months.</p><p>Protara said it expects international site expansion to accelerate enrollment and plans to share initial data from 12 months in mid-2025.</p><p>The investigational drug showed a favorable safety and tolerability profile, with no grade 2 or greater treatment-related adverse events, the company added.</p><p>Shares of the company surged more than 128% in recent premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Protara Says Phase 2 Bladder Cancer Trial Shows 72% Complete Response Rate at 6 Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProtara Says Phase 2 Bladder Cancer Trial Shows 72% Complete Response Rate at 6 Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-05 22:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Protara <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TARA) said Thursday that its investigational therapy TARA-002 demonstrated a complete response rate of 72% at six months in a phase 2 trial involving patients with non-muscle invasive bladder cancer.</p><p>The company said the complete response rate across Bacillus Calmette-Guerin exposures reached 70% at any time, with 100% of patients maintaining complete response and two of three patients sustaining response at nine months.</p><p>Protara said it expects international site expansion to accelerate enrollment and plans to share initial data from 12 months in mid-2025.</p><p>The investigational drug showed a favorable safety and tolerability profile, with no grade 2 or greater treatment-related adverse events, the company added.</p><p>Shares of the company surged more than 128% in recent premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TARA","symbol_name":"ArTara Therapeutics, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2489430468","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489430468","pubTimestamp":1733408344,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Protara Therapeutics  said Thursday that its investigational therapy TARA-002 demonstrated a complete response rate of 72% at six months in a phase 2 trial involving patients with non-muscle invasive bladder cancer.The company said the complete response rate across Bacillus Calmette-Guerin exposures reached 70% at any time, with 100% of patients maintaining complete response and two of three patients sustaining response at nine months.Protara said it expects international site expansion to accelerate enrollment and plans to share initial data from 12 months in mid-2025.The investigational drug showed a favorable safety and tolerability profile, with no grade 2 or greater treatment-related adverse events, the company added.Shares of the company surged more than 128% in recent premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TARA":"ArTara Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Protara称2期膀胱癌试验显示6个月时完全缓解率为72%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TARA":0.9},"content_text":"Protara Therapeutics (TARA) said Thursday that its investigational therapy TARA-002 demonstrated a complete response rate of 72% at six months in a phase 2 trial involving patients with non-muscle invasive bladder cancer.The company said the complete response rate across Bacillus Calmette-Guerin exposures reached 70% at any time, with 100% of patients maintaining complete response and two of three patients sustaining response at nine months.Protara said it expects international site expansion to accelerate enrollment and plans to share initial data from 12 months in mid-2025.The investigational drug showed a favorable safety and tolerability profile, with no grade 2 or greater treatment-related adverse events, the company added.Shares of the company surged more than 128% in recent premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}